Dual blockade of angiotensin‐II and aldosterone suppresses the progression of a non‐diabetic rat model of steatohepatitis

Abstract

Dual blockade of AT-II and Ald suppresses the progression of a non-diabetic rat model of steatohepatitis. Because both agents are widely and safely used in clinical practice, this combination therapy could be an effective new strategy against steatohepatitis in the future.

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

“…Immunohistochemical staining with a-smooth muscle actin (a-SMA) (DAKO, Kyoto, Japan) was performed as previously described [15,19]. Stained sections were analyzed using ImageJ software (National Institutes of Health).…”

“…Stained sections were analyzed using ImageJ software (National Institutes of Health). A total of six microscopic visual fields (magnification 409) per specimen in ten rats were used for ImageJ analysis as previously described [19]. Histological features were semi-quantitatively assessed in accordance with the NAFLD scoring system (NAS), as previously described [20].…”

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

“…Although ALT levels in the CDAA‐fed rats were significantly more elevated than those in the controls, the inflammation in the CDAA‐diet model was not as severe as that in the CCl4‐induced model of liver fibrosis, especially in the early stage . The CDAA‐diet model is widely used as a NASH model as it shows histological sequences similar to those shown in chronic liver diseases …”

“…Stained sections were analyzed using ImageJ software (version 1.47; https://imagej.nih.gov/ij/; National Institutes of Health, Bethesda, MD, USA). Six microscopic visual fields (magnification ×40) per specimen from 10 rats were used for ImageJ analysis, as previously described . Histological features were semiquantitatively assessed according to the NAFLD scoring system as previously described …”

Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis

“…For all experimental groups, 5‐μm thick sections of formalin‐fixed and paraffin‐embedded liver specimens were routinely subjected to hematoxylin–eosin staining. Sirius red staining to evaluate liver fibrosis, immunohistochemical staining probing for α‐smooth muscle actin (α‐SMA; Dako, Kyoto, Japan), and Oil red O staining to evaluate liver steatosis were used as previously described . Glutathione S‐transferase placental form (GST‐P) was used to detect hepatic preneoplastic lesions.…”